Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying budoprutug, an investigational humanized antibody that targets CD19 cells, in adults aged 18 to 65 with active and seropositive systemic lupus erythematosus SLE who have not responded adequately to standard treatments. This Phase 1b open-label study focuses on assessing the safety and tolerability of budoprutug, as well as its behavior in the body and early signs of effectiveness. Participants will receive a single intravenous infusion of budoprutug at one of several ascending dose levels. The study will monitor how the drug affects B cell counts and antibody levels in the blood over time following the infusion. Multiple dose groups will be evaluated to understand safety and the drugs movement and action in the body. Throughout the study, participants will be closely observed for treatment-emergent adverse events and changes in vital signs and laboratory tests up to 24 weeks after dosing. Researchers will also measure budoprutugs concentration in the blood and immune responses, including the presence of anti-drug antibodies. The total monitoring period helps ensure comprehensive safety and pharmacological data collection.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of DDY391 in adults with Sjgrens Disease SjD through a Phase 2ab randomized, double-blind, placebo-controlled study. The trial aims to determine the dose-response relationship of DDY391 to support dose selection for Phase 3. The study is conducted across multiple centers and involves participants diagnosed according to specific classification criteria. Participants will be assigned to one of several groups receiving different dose levels of DDY391 or a matching placebo. The study is divided into three parts Parts A, B, and C, with a screening period lasting up to 8 weeks, followed by a 52-week treatment period. At the 24-week visit, participants initially on placebo will be re-randomized to receive DDY391 at dose level 1 or 2. After treatment, there is a 4-week safety follow-up period. During the trial, participants will undergo various assessments including changes from baseline in disease activity scores such as ESSDAI and ESSPRI, and evaluations of symptom severity. Safety will be closely monitored through the recording of adverse events. The total participation duration includes screening, treatment, and safety follow-up, extending over approximately 64 weeks.
Actively Recruiting
Researchers are evaluating the efficacy and safety of enpatoran in adults with active cutaneous manifestations of lupus erythematosus, with or without systemic disease, in this global, multicenter Phase 3 study. The study aims to assess enpatorans effect over 24 weeks compared to a placebo, focusing on skin disease activity and safety outcomes. Participants include those diagnosed with discoid, subacute cutaneous lupus, or active acute cutaneous lupus alongside systemic lupus erythematosus. Participants will receive either enpatoran tablets or matching placebo tablets orally twice daily for 24 weeks Day 1 to Day 168, alongside investigator-recommended standard of care. The study includes scheduled visits every 4 weeks, with a telehealth visit at Week 2. The intervention is administered as film-coated tablets, and the treatment period lasts for 24 weeks within an overall study duration of up to 35 weeks. During the study, participants will be monitored through regular visits every 4 weeks to assess skin disease using the Cutaneous Lupus Erythematosus Disease Area and Severity Index CLASI and other clinical measurements. Researchers will evaluate skin improvement, lupus disease activity, adverse events, laboratory parameters, and corticosteroid use. Safety and treatment effects will be closely followed during and after the treatment period, with the primary outcome assessed at Week 24.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of subcutaneous anifrolumab injections compared to placebo in adults with moderate to severe Idiopathic Inflammatory Myopathies IIM, including polymyositis PM and dermatomyositis DM. This Phase III, multicenter, randomized, placebo-controlled, and double-blind study adds anifrolumab or placebo to participants standard of care treatment to assess overall disease activity. Participants receive either anifrolumab or a matched placebo by subcutaneous injection once weekly for 52 weeks while continuing their standard treatments. After this period, all participants have the option to receive open-label anifrolumab weekly for an additional 52 weeks. This design allows researchers to compare the effects of anifrolumab against placebo and then observe longer-term effects when all receive anifrolumab. Throughout the study, participants undergo regular assessments including the Total Improvement Score TIS at 52 weeks as the main outcome. Additional evaluations include muscle strength testing, corticosteroid dosage monitoring, skin disease activity, and itch severity up to 52 weeks. Safety and disease activity improvements for both PM and DM participants are closely monitored. The study lasts up to approximately two years, including both blinded and open-label treatment phases.
Actively Recruiting
Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.
Actively Recruiting
Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.
Actively Recruiting
This research aims to evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle using the Galvani System in people with active rheumatoid arthritis RA. Participants must have active RA with an inadequate response or intolerance to at least two biologic Disease Modifying Anti-Rheumatic Drugs DMARDs or JAK inhibitors. The study includes four distinct periods a randomized control trial, an open label phase, a treat-to-target phase, and a long-term follow-up, to thoroughly assess the treatment over time. Participants who receive the implantable system will be randomly assigned to either active stimulation or sham stimulation for 12 weeks in the first period. In the second period, responders to stimulation continue it, while non-responders or those who had sham stimulation receive an approved RA drug, baricitinib, for 12 weeks. In the third period, participants showing improvement but still with RA symptoms receive combined therapy of stimulation and baricitinib for up to 24 weeks. The fourth period provides a long-term safety follow-up lasting up to 5 years, during which participants may receive stimulation with other standard treatments as judged appropriate. Throughout the study, participants will undergo assessments including monitoring for adverse events, changes in RA disease activity scores, inflammatory markers, and questionnaires on physical and mental health. The study will track safety and tolerability during each period, with long-term follow-up to observe ongoing effects. The total participation duration extends over several years, with detailed monitoring to evaluate the implantable devices performance and impact on RA symptoms.
Actively Recruiting
Researchers are studying the effects of lunsekimig, given as a subcutaneous injection, in adults aged 40 to 80 years with chronic obstructive pulmonary disease COPD that is not well controlled and characterized by an eosinophilic phenotype. This Phase 2bPhase 3, randomized, double-blind, placebo-controlled study compares two dosing regimens of lunsekimig against placebo to evaluate its efficacy, safety, and tolerability over a prolonged period. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a treatment period of about 48 weeks. The study includes a screening phase lasting up to 4 weeks before treatment, followed by an 8-week follow-up after the intervention, totaling up to 60 weeks of participation. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires like the Chronic Airways Assessment Test CAAT, and monitoring of exacerbations and adverse events. Researchers will measure the rate of moderate to severe COPD exacerbations as the primary outcome. Safety labs, antibody testing, and drug concentration monitoring will also occur. Participants will be monitored throughout the study duration, including follow-up after treatment ends.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of MTX-474, a monoclonal antibody, in adults with diffuse cutaneous systemic sclerosis dcSSc, a condition causing skin thickening and organ involvement. This Phase 2 randomized, double-blind, placebo-controlled trial aims to compare MTX-474 with a placebo to better understand its impact on the skin symptoms of dcSSc. Participants will be randomly assigned to receive either MTX-474 or a placebo via intravenous infusion every 4 weeks, from the start of the study through Week 20. The study allows some participants to continue approved dcSSc treatments under specific conditions. Treatment visits continue through Week 24, followed by a safety follow-up visit at Week 28. Throughout the study, participants will have regular skin assessments using the Modified Rodnan Skin Score mRSS, lung function tests including spirometry and DLCO, and imaging with high-resolution CT scans at screening and Week 24. Skin biopsies will be taken at baseline and Week 12, and blood samples will be collected at screening, baseline, and every 4 weeks until Week 28 to monitor safety, drug levels, and biomarkers. The main outcome measured is the change in skin thickness from the start to Week 24, along with safety and tolerability assessments extending through Week 28.
Actively Recruiting
Researchers are conducting the FLEX Registry, a large-scale, population-based study focusing on patients with stage I to III breast cancer who have undergone MammaPrint and BluePrint testing on their primary breast tumors. This observational registry aims to gather comprehensive full genome expression data linked with clinical information to explore new gene associations that may have prognostic or predictive value. The design is adaptive, allowing additional targeted substudies and arms to be added over time for more specific investigations. All participants will have their tumor samples tested using MammaPrint and BluePrint through the full-genome testing array provided by Agendia. Treatment decisions are made by the treating physician following NCCN guidelines or recognized alternatives, with no specific treatment mandated by the study. The registry plans to enroll about 30,000 patients from more than 125 US institutions, encompassing various treatment arms detailed in study appendices. Participants will have clinical data collected online at multiple time points at enrollment, during treatment, and at 1, 3, 5, and 10 years after diagnosis. This long-term follow-up allows researchers to study gene expression alongside clinical outcomes, supporting the creation of subgroup analyses and future targeted trials. The primary outcomes include establishing a large-scale full genome expression registry and providing infrastructure for examining smaller patient groups over the 10-year study period.
1-10 of 18
1